Anne Portwich

A multi-award winning Irish company innovating in womens health. Nua Surgical was developed out of BioInnovate Ireland and is dedicated to innovating in Womens Health. The team are currently pursuing solutions to unmet clinical needs in obstetric surgery. In 2018, the founding team secured a 2 year Research and Commercialisation Grant from Enterprise Ireland to develop the SteriCISION C-Section Retractor at the University of Galway. Brief Overview of Achievements: 𝟮𝟬𝟭𝟴 - Our founding team were awarded an Enterprise Ireland Commercialisation Fund to bring the project from early stage concept to commercialisation.  This was based at the University of Galway. 𝟮𝟬𝟭𝟵 - Nua Surgical was chosen as one of seven start-ups between Ireland and the U.S. to participate in the Blackstone-backed accelerator LaunchPad Lift powered by Techstars. - Our CEO was named Best Senior Entrepreneur at the EIT Health Alumni Needs-Led Innovation Showcase in Lisbon, Portugal. 𝟮𝟬𝟮𝟬 - One of 16 UK and Ireland Start-ups to be awarded €40,000 through the EIT Health Headstart Programme. - One of 15 winners for the national HIHI Healthcare Innovation Call 2020.   - Winner of the InterTrade Ireland Seedcorn Competition, securing €100,000.   𝟮𝟬𝟮𝟭 - Winners of the Global Healthy Mom and Baby Innovation Competition 2.0, run by Parkview Health and MATTER (USA).  𝟮𝟬𝟮𝟮 - Won MedTech category of the Global Tech For Good Competition run by Empact Ventures, Hays and the NIHR. - Winner of the MedTech Category at the National Start-Up Awards, followed by overall Grand-Prix Winner at the famous Dublin City Hall ceremony.  𝟮𝟬𝟮𝟯 - The only non-US company to participate in Cohort 15 of the prestigious Texas Medical Center HealthTech Accelerator. - 1 of 8 Irish finalists for the KPMG Global Tech Innovation Awards. - Emerging MedTech Company of the Year at the prestigious Irish MedTech Awards. - Double winners at the 2023 National HealthTech Innovation Awards.

Neurovascular medtech startup

We enable Cardiologists to save lives through exceptional decision-making accuracy.

Recommended by 98% of physicians and 90% of users, INNOVO is the perfect solution for treating stress urinary incontinence. Safe, effective and FDA-cleared, INNOVO offers the only clinically-proven, wearable and truly non-invasive solution for stress urinary incontinence (SUI). Using unique multipath™ technology, INNOVO targets the weakened pelvic floor muscles, delivering 180 perfect and complete pelvic floor contractions over each 30-minute session.

About iSTAR Medical iSTAR Medical is committed to delivering breakthrough eye care solutions. Our most advanced product, MINIject, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness[1] – and we are aiming to seek market approval in the US. We believe MINIject’s unique tissue-integrating capabilities unlock a safer, and more effective option for patients. We are building an exceptional team and pipeline of best-in-class products such as MINIject to establish new treatment paradigms in eye care conditions with the highest patient needs. About MINIject® MINIject is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject combines the unique porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications. About Glaucoma Glaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form.[1][2] IOP reduction, through medication or surgery, helps delay disease progression.[3] MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile.[2] MINIject is potentially best-in-class for its promising long-term efficacy and safety. [1] Jonas JB, Aung T, Bourne RR et al. “Glaucoma”. Lancet 2017; 390: 2083–93 [2] Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021. https://www.market-scope.com/pages/reports/267/2021-glaucoma-surgical-device-market-report [3] “European Glaucoma Society Terminology and Guidelines for Glaucoma”, 4th Edition: British Journal of Ophthalmology. 2017;101:1-195 https://bjo.bmj.com/content/101/5/73 MINIject is a registered trademark in the European Union.

Vivasure Medical Ltd. is an ISO 13485 registered medical device company based at Europe’s leading MedTech cluster in Galway, Ireland. Founded in 2009, the company is led by an experienced management team and backed by a syndicate of international venture capital investors and state agencies. The company has developed and patented the world’s first fully absorbable, patch-based closure device specifically designed to seal large-bore arteriotomies in endovascular procedures. Please, refer to our website for further information.

ViCentra BV, Medical Devices, Utrecht Founded in 2013 in Utrecht, The Netherlands, ViCentra is a leading early stage commercial company focused on the development, manufacturing and commercialisation of the Kaleido insulin pump designed to help people with diabetes live life on their own terms. Driven by our belief in the power of innovative healthcare products that put the people first and a desire to be meaningfully different, Kaleido aims to reduce the impact that diabetes can have on daily life.

Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s stroke therapy platform, the EmboTrap®II Revascularization Device, is CE marked and commercially available in Europe. The device has been available for investigational use only in the United States. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke. In April 2017, Codman Neuro announced the acquisition of Neuravi, which is now part of the Johnson and Johnson family of medical device companies. Neuravi was founded in 2009 and is headquartered in Galway, Ireland.

MedEye was founded to improve medication safety in healthcare institutions. The company was founded in 2009 by three MIT graduates and is now headquartered in the Netherlands. It developed an innovative medication safety solution for bedside medication verification. MedEye shortens the time it takes nurses to verify and document medication administrations, increasing safety and efficiency. Through a combination of innovative hardware and software and seamless integration with hospital information systems, MedEye enables nurses to automatically verify medication at the bedside, thus ensuring that patients get the right medication, in the right dose and at the right time.

Mendor is committed to improving the daily treatment of diabetes around the world. We are proud to develop, manufacture and market new solutions for glucose monitoring and analysis that make a difference in the quality of life and empower people with diabetes.

Nexstim is a Finnish, globally operating medical technology company. Founded in 2000 in Helsinki, Finland, Nexstim is committed to improving the quality of life of patients with significant unmet clinical needs. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain. In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

ActoGeniX is a biopharmaceutical company, focused on the development and commercialization of a new generation of biological drugs; ActoBiotics™. ActoBiotics™ are created using TopAct™, ActoGeniX’s versatile and proprietary technology platform. They can be orally administered and target receptors and pathways in gastrointestinal tissues. This novel class of biopharmaceuticals has the potential to treat a broad range of severe diseases. With several ActoBiotics™ in various stages of clinical and preclinical development, ActoGeniX’s initial focus is on areas with unmet need in gastrointestinal, immunological and metabolic diseases.

A multi-award winning Irish company innovating in womens health. Nua Surgical was developed out of BioInnovate Ireland and is dedicated to innovating in Womens Health. The team are currently pursuing solutions to unmet clinical needs in obstetric surgery. In 2018, the founding team secured a 2 year Research and Commercialisation Grant from Enterprise Ireland to develop the SteriCISION C-Section Retractor at the University of Galway. Brief Overview of Achievements: 𝟮𝟬𝟭𝟴 - Our founding team were awarded an Enterprise Ireland Commercialisation Fund to bring the project from early stage concept to commercialisation.  This was based at the University of Galway. 𝟮𝟬𝟭𝟵 - Nua Surgical was chosen as one of seven start-ups between Ireland and the U.S. to participate in the Blackstone-backed accelerator LaunchPad Lift powered by Techstars. - Our CEO was named Best Senior Entrepreneur at the EIT Health Alumni Needs-Led Innovation Showcase in Lisbon, Portugal. 𝟮𝟬𝟮𝟬 - One of 16 UK and Ireland Start-ups to be awarded €40,000 through the EIT Health Headstart Programme. - One of 15 winners for the national HIHI Healthcare Innovation Call 2020.   - Winner of the InterTrade Ireland Seedcorn Competition, securing €100,000.   𝟮𝟬𝟮𝟭 - Winners of the Global Healthy Mom and Baby Innovation Competition 2.0, run by Parkview Health and MATTER (USA).  𝟮𝟬𝟮𝟮 - Won MedTech category of the Global Tech For Good Competition run by Empact Ventures, Hays and the NIHR. - Winner of the MedTech Category at the National Start-Up Awards, followed by overall Grand-Prix Winner at the famous Dublin City Hall ceremony.  𝟮𝟬𝟮𝟯 - The only non-US company to participate in Cohort 15 of the prestigious Texas Medical Center HealthTech Accelerator. - 1 of 8 Irish finalists for the KPMG Global Tech Innovation Awards. - Emerging MedTech Company of the Year at the prestigious Irish MedTech Awards. - Double winners at the 2023 National HealthTech Innovation Awards.

EQT Life Sciences, formerly LSP, is one of Europe’s largest and most experienced healthcare investors, targeting innovative life sciences and health care companies.

A global private markets firm. 30+ years of unlocking returns and growth for investors beyond public markets.

Neurovascular medtech startup

We enable Cardiologists to save lives through exceptional decision-making accuracy.